BPDCN International Registry shared a post on LinkedIn:
“Genomics is starting to clarify why BPDCN behaves so aggressively – and which markers might help us diagnose and follow it more precisely.
Our next BPDCN paper of the day focuses on the mutational landscape of BPDCN and a potential biomarker.
Paper #2 – Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience
Oncotarget. 2025;16:495–507.
Targeted NGS in 21 BPDCN patients showed frequent mutations in TET2 (57%) and ASXL1 (33%), with additional recurrent alterations in NRAS, SRSF2, ZRSR2, and KMT2D.
The study also highlights CCDC50 as markedly overexpressed in BPDCN compared to AML/CMML, with levels decreasing in remission – supporting its role as a potential diagnostic and disease‑monitoring biomarker.
The BPDCN International Registry (NCT05430971) is actively enrolling centers worldwide. Interested in contributing real‑world data? bpdcn@immonc.org”
Title: Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience
Authors: Sravya Konanty, Shuhua Zhou, Fengying Huang, Liying Yan, Jinghong Xu, Juehua Gao
Other articles about BPDCN on OncoDaily.